VYVANSE Drug Profile, 2023: VYVANSE (lisdexamfetamine dimesylate) drug patents, FDA exclusivity, litigation, drug prices, sales revenues (DrugPatentWatch Business Intelligence Reports)
VYVANSE Drug Profile, 2023: VYVANSE (lisdexamfetamine dimesylate) drug patents, FDA exclusivity, litigation, drug prices, sales revenues (DrugPatentWatch Business Intelligence Reports)
Description :
VYVANSE Drug Profile, 2023This report focuses on VYVANSE and covers the following critical aspects of this drug:United States patentsFDA Paragraph IV patent challengesDistrict Court patent litigationEuropean supplementary protection certificates (SPCs)Clinical trialsDrug pricesAnnual sales revenuesFinished product suppliersRaw active pharmaceutical ingredient (API) sourcesFREE UPDATE: Send your receipt to DrugPatentWatch within 30 days for a free update